[{"id":"a3ff3bf1-6fbc-4e00-b8e0-454d7fb78cce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05687136","created_at":"2023-01-18T15:59:53.342Z","updated_at":"2025-02-25T13:41:23.007Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors","source_id_and_acronym":"NCT05687136","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18","pipe":" | ","alterations":" ATM mutation • ARID1A mutation","tags":["ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/07/2024","start_date":" 06/07/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-02-21"},{"id":"2a6d7e4f-c35c-4e6b-8dc6-72106bb36c61","acronym":"","url":"https://clinicaltrials.gov/study/NCT04750954","created_at":"2023-12-06T16:15:46.614Z","updated_at":"2025-02-25T13:53:37.832Z","phase":"Phase 1","brief_title":"Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors","source_id_and_acronym":"NCT04750954","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/22/2021","start_date":" 07/22/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-20"},{"id":"9ae6d61c-52ac-447d-9656-ee355853d0dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04068194","created_at":"2023-11-15T17:14:49.418Z","updated_at":"2025-02-25T13:52:57.960Z","phase":"Phase 1/2","brief_title":"Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies","source_id_and_acronym":"NCT04068194","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • peposertib (M3814)"],"overall_status":"Recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"939d1cf5-27ac-48f1-9f3d-96f6a19b535a","acronym":"NRG-HN008","url":"https://clinicaltrials.gov/study/NCT04533750","created_at":"2021-01-29T07:21:21.551Z","updated_at":"2024-07-02T16:34:37.751Z","phase":"Phase 1","brief_title":"Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin","source_id_and_acronym":"NCT04533750 - NRG-HN008","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" CDKN2A negative","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • peposertib (M3814)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/20/2021","start_date":" 12/20/2021","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-06-06"},{"id":"e3f709a4-4377-4abd-8838-8424d0acce76","acronym":"","url":"https://clinicaltrials.gov/study/NCT03983824","created_at":"2021-01-18T19:35:36.667Z","updated_at":"2024-07-02T16:34:59.061Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03983824","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RARA • PML • CD4","pipe":"","alterations":" ","tags":["RARA • PML • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • mitoxantrone • peposertib (M3814) • Starasid (cytarabine ocfosfate)"],"overall_status":"Suspended","enrollment":" Enrollment 48","initiation":"Initiation: 05/05/2020","start_date":" 05/05/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"12ef23c8-0f04-4348-90aa-89217bc8e0c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04555577","created_at":"2021-07-05T17:32:33.242Z","updated_at":"2024-07-02T16:35:03.500Z","phase":"Phase 1","brief_title":"Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma","source_id_and_acronym":"NCT04555577","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • peposertib (M3814)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 09/20/2020","start_date":" 09/20/2020","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2024-05-15"},{"id":"39600657-9818-4335-b9b0-80fa4fd397be","acronym":"EMR100036-001","url":"https://clinicaltrials.gov/study/NCT02316197","created_at":"2021-01-18T10:58:29.901Z","updated_at":"2025-02-25T14:49:55.417Z","phase":"Phase 1","brief_title":"Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT02316197 - EMR100036-001","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 12/31/2014","start_date":" 12/31/2014","primary_txt":" Primary completion: 06/29/2017","primary_completion_date":" 06/29/2017","study_txt":" Completion: 06/29/2017","study_completion_date":" 06/29/2017","last_update_posted":"2020-04-28"}]